A5016467089- Brain Metastases and Treatment
- Lung Cancer Research Studies
- Cancer Genomics and Diagnostics
- Advanced biosensing and bioanalysis techniques
- Lung Cancer Treatments and Mutations
- Chemical Reactions and Isotopes
- Advanced Breast Cancer Therapies
- Chronic Lymphocytic Leukemia Research
- Pharmacogenetics and Drug Metabolism
- Biosimilars and Bioanalytical Methods
- X-ray Diffraction in Crystallography
- Cancer Treatment and Pharmacology
- Crystallization and Solubility Studies
- Lymphoma Diagnosis and Treatment
- Peripheral Neuropathies and Disorders
- DNA Repair Mechanisms
- Computational Drug Discovery Methods
- Acute Lymphoblastic Leukemia research
- Fluorine in Organic Chemistry
- Click Chemistry and Applications
- Urticaria and Related Conditions
- Pathogenesis and Treatment of Hiccups
- Analytical Methods in Pharmaceuticals
- PARP inhibition in cancer therapy
- Cardiac Fibrosis and Remodeling
National Cancer Institute
2023-2025
National Institutes of Health
2023-2024
Center for Cancer Research
2023-2024
University of Maryland Medical Center
2024
National Center for Advancing Translational Sciences
2024
University of Maryland, Baltimore
2024
Government of the United States of America
2023
University of Oxford
2020
Trinity College Dublin
2018
University College Dublin
2018
The identification of oncogenic mutations in diffuse large B-cell lymphoma (DLBCL) has led to the development drugs that target essential survival pathways, but whether targeting multiple pathways may be curative DLBCL is unknown.
Preclinical data showed that prophylactic, low-dose temozolomide (TMZ) significantly prevented breast cancer brain metastasis. We present results of a phase I trial combining T-DM1 with TMZ for the prevention additional metastases after previous occurrence and local treatment in patients HER2+ cancer.Eligible had were within 12 weeks whole radiation therapy (WBRT), stereotactic radiosurgery, and/or surgery. Standard doses administered intravenously every 21 days (3.6 mg/kg) was given orally...
Biological investigation of a new Tröger's base–Ru(<sc>ii</sc>)–curcumin conjugate is described.
Objective To report the efficacy and safety of interferon‐β (IFNβ) neutralizing monoclonal antibody (dazukibart), followed by treatment with anti‐IFNAR1 (anifrolumab), in a patient STING‐associated vasculopathy onset infancy (SAVI) who had vasculitic ulcers systemic inflammation refractory to Janus kinase inhibition (JAKi). Methods A SAVI de novo STING1 p.(Asn154Ser) mutation, known pathogenic variant, uncontrolled disease received twenty‐one doses dazukibart under compassionate use...
Atezolizumab, a humanized monoclonal antibody against programmed cell death ligand 1 (PD-L1), was initially approved in 2016, around the same time that sponsor published minimum serum concentration to maintain saturation of receptor occupancy (6 μg/mL). The dose regimen 1200 mg every 3 weeks (q3w) subsequently modified 840 q2w or 1680 q4w through pharmacokinetic simulations. Yet, each standard yields steady-state trough concentrations (C
Abstract The initially approved dosage regimens of 840 mg every 2 weeks, 1200 3 and 1680 4 weeks are considered excessive concerning the specified minimum effective concentration 6 ug/mL significant exposure-response relationship with Adverse Events Special Interest (AESI). Our previous research, demonstrated through simulation, indicated that an extended-interval dosing regimen (840 weeks) after two standard loading doses maintained efficacy a nonsignificant AESI.In alignment FDA's...
<title>Abstract</title> Lenalidomide maintenance is associated with a significantly improved progression-free in patients newly diagnosed multiple myeloma. Maintenance lenalidomide generally well tolerated; however, diarrhea common side effect and bile acid malabsorption has been suggested as an underlying mechanism. We conducted single arm phase 2 trial of colesevelam, binder, for lenalidomide-associated Patients were treated colesevelam daily starting at 1250 mg (2 tablets 625 mg) 12...
<p>Supplemental Fig 2. Total mutation Burden by MB.</p>
<p>Supplemental Methods</p>
<p>Supplemental Fig. 3. ERB-B-2 Status of Patients.</p>
<p>Supplemental Fig. 1. Neurocognitive assessments comparing patients presenting progression versus no progression.</p>
<p>Supplemental Fig. 4. Histogram illustrating ERBB2 relative copy number in plasma and CSF cfDNA samples from 12 patients during their T Tsamples T-DM1/TMZ combination therapy.</p>
<p>Supplemental Fig. 1. Neurocognitive assessments comparing patients presenting progression versus no progression.</p>
<p>Supplemental Fig 2. Total mutation Burden by MB.</p>
<p>Supplemental Methods</p>
<p>Supplemental Fig. 4. Histogram illustrating ERBB2 relative copy number in plasma and CSF cfDNA samples from 12 patients during their T Tsamples T-DM1/TMZ combination therapy.</p>
<p>Supplemental Fig. 3. ERB-B-2 Status of Patients.</p>